Sixtin 2.5 mg (Tablet)

Indications

• Adjunct to diet and exercise
• Improves glycemic control
• Adults with type 2 diabetes mellitus
• Not indicated for type 1 diabetes mellitus or diabetic ketoacidosis

Pharmacology

• Inhibits dipeptidyl peptidase IV (DPP-IV) enzyme
• Elevates circulating levels of GIP and GLP-1
• Stimulates insulin secretion in a glucose dependent manner
• Reduces fasting and postprandial plasma glucose concentration

Dosage

• Recommended dosage of 2.5 mg or 5 mg once daily
• No dosage adjustment for mild renal impairment
• 2.5 mg once daily for moderate or severe renal impairment or ESRD
• Dosage adjustment with concomitant use of strong CYP3A4/5 inhibitors

Administration

• May be taken with or without food

Interaction

• Increased risk of hypoglycaemia with concomitant sulfonylureas
• Increased serum levels with CYP3A4/5 inhibitors
• Concomitant CYP3A4 inducers may reduce the glycaemic lowering effect

Contraindications

• Type 1 diabetes
• Diabetic ketoacidosis

Side Effects

• Pancreatitis
• Heart Failure
• Hypoglycemia with Concomitant Use of Sulfonylurea or Insulin
• Hypersensitivity Reactions
• Severe and disabling arthralgia
• Bullous pemphigoid

Pregnancy & Lactation

• Category B

Precautions & Warnings

• Moderate and severe renal impairment
• Pregnancy and lactation

Use in Special Populations

• No dosage adjustment needed for mild renal impairment
• 2.5 mg once daily for moderate to severe including with ESRD requiring hemodialysis
• No dosage adjustment for hepatic impairment

Therapeutic Class

• Dipeptidyl Peptidase-4 (DPP-4) inhibitor

Storage Conditions

• Store between 20-25 degrees Celsius

Related Brands

• Sixtin 5 mg (Tablet) - drug-international-ltd